Dermatologic Adverse Events in Prostate Cancer Patients Treated with the Androgen Receptor Inhibitor Apalutamide.

Prostate cancer (PCa) patients treated with apalutamide frequently develop rash. We aim to characterize apalutamide-related dermatologic adverse events (dAE) and management.

We assessed 303 PCa patients treated with apalutamide.